FibroGen, Inc.

FibroGen, Inc. is a biotechnology company focused on developing and commercializing novel therapies for serious and life-threatening diseases, particularly in the field of oncology. Their core focus areas include chemotherapy-induced anemia, prostate cancer, and anemia in chronic kidney disease (CKD). They are committed to leveraging the body's natural pathways to develop treatments that have the potential to change lives.

FibroGen boasts a robust pipeline of potential first-in-class medicines, including Roxadustat, an oral HIF-PH inhibitor for chemotherapy-induced anemia and CKD anemia, and FG-3246, a fully human antibody-drug conjugate for metastatic castration-resistant prostate cancer. The company has a global presence with operations in China, where Roxadustat is already approved for CKD anemia and is in Phase 3 clinical development for CIA. They also have numerous strategic partnerships with companies such as Astellas, AstraZeneca, Eluminex, Fortis, and HiFiBiO, which further enhance their reach and capabilities.

FibroGen offers a flexible work environment with a subsidized public transit commuter program, onsite electric vehicle charging stations, a flexible work from home policy, and global access to video conferencing and meetings. This fosters a balance between work and personal life, and promotes employee well-being.

FibroGen offers a comprehensive benefits package designed to support employee well-being and financial security. These include comprehensive healthcare coverage with PPO or HMO options, prescription drug, vision, and dental benefits, as well as on-site fitness facilities with equipment, classes, and personal training. Employees also have access to company-paid short-term and long-term disability coverage, life insurance, and business travel accident insurance. Financial benefits include an annual bonus program, a 401(k) retirement plan with company matching, an incentive stock plan, an employee stock purchase plan, flexible spending accounts, and pre-tax commuter programs. Other benefits include generous vacation time, paid holidays, personal wellness days, tuition reimbursement, employee sponsorship for professional development, and an employee assistance program.

FibroGen, Inc. is a biotechnology company dedicated to improving the lives of people globally by developing innovative therapies for serious and life-threatening diseases. They are focused on accelerating the development of novel therapies at the frontiers of cancer biology, particularly in the areas of chemotherapy-induced anemia, metastatic castration-resistant prostate cancer, and anemia associated with chronic kidney disease. Their commitment to innovation is evident in their pipeline of potential first-in-class medicines, which aim to leverage the body’s natural pathways to treat cancer and its related conditions.

FibroGen promotes a culture of collaboration, excellence, empowerment, integrity, and respect for people. They value diverse perspectives and encourage employees to share ideas and take on new challenges. They are committed to fostering individual growth and promoting an environment that supports continued learning. FibroGen believes in treating each other with dignity and respect, while striving to create a safe and healthy environment for both employees and patients.

FibroGen is committed to fostering a diverse, equitable, and inclusive workplace. They believe in empowering employees, upholding integrity, and demonstrating respect for everyone. Their efforts include comprehensive recruiting and retention strategies, competitive compensation and benefits, employee development programs, and pay transparency initiatives. They regularly review and assess their practices to ensure a culture of inclusion and belonging, and actively promote diversity within their workforce. They also support career opportunities for underrepresented groups through internships and partnerships with organizations like NextGene Girls and Young Community Developers.